Torbjörn Tomson, MD, PhD, The Karolinska Institute, Solna, Sweden, discusses the burden associated with epilepsy, which affects not only the patients but also the caregivers and societies, and tends to be greater in patients with treatment-resistant epilepsy. From a patient’s perspective, the burden of epilepsy may be due to stigma, comorbidities, increased risks of injuries, and risks associated with seizures, including premature death. Epilepsy burden is also associated with poor seizure control. In order to reduce the stigma around epilepsy and improve quality of life, effective community education programs are essential. Additionally, the improvement of epilepsy treatments can increase the proportion of patients with complete control of seizures and reduce the disease burden. This interview took place during the European Academy of Neurology 2021 congress.
Grants from Eisai, GSK, UCB, Bial, Sanofi, Teva and GW Pharma in support of EURAP, The International Antiepileptic Drugs and Pregnancy Registry.
Speakers or advisory board honoraria from Eisai, Sanofi, Sun Pharma, Arvelle, and GW Pharma.